188 related articles for article (PubMed ID: 19833389)
1. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
Véronèse L; Tchirkov A; Richard-Pebrel C; Ledoux-Pilon A; Fleury J; Chaleteix C; Goumy C; Gouas L; Berger MG; Vago P; Bay JO; Tournilhac O
Leuk Res; 2010 Apr; 34(4):e94-6. PubMed ID: 19833389
[No Abstract] [Full Text] [Related]
2. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
3. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
Campiotti L; Appio L; Solbiati F; Ageno W; Venco A
Leuk Res; 2009 Nov; 33(11):e212-3. PubMed ID: 19589593
[No Abstract] [Full Text] [Related]
4. Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
Park TS; Cheong JW; Kim SJ; Lee KW; Song J; Lee KA; Suh B; Song S; Choi JR
Cancer Genet Cytogenet; 2009 Apr; 190(1):46-8. PubMed ID: 19264234
[No Abstract] [Full Text] [Related]
5. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
Faber E; Mojzikova R; Plachy R; Rozmanova S; Stastny M; Divoka M; Jarosova M; Indrak K; Divoky V
Leuk Res; 2010 Apr; 34(4):e91-3. PubMed ID: 19811824
[No Abstract] [Full Text] [Related]
6. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
7. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
8. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
9. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
[No Abstract] [Full Text] [Related]
10. Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.
Breccia M; Muscaritoli M; Cannella L; Loglisci G; Santopietro M; Alimena G
Leuk Res; 2010 May; 34(5):e122-4. PubMed ID: 20018374
[No Abstract] [Full Text] [Related]
11. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Gattenlohner S; Völker HU; Etschmann B; Einsele H; Müller-Hermelink HK
Am J Hematol; 2009 May; 84(5):306-7. PubMed ID: 18951468
[No Abstract] [Full Text] [Related]
12. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
13. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
14. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
Krämer A; Reiter A; Kruth J; Erben P; Hochhaus A; Müller M; Cross NC; Jones AV; Ho AD; Hensel M
Lancet Oncol; 2007 Jul; 8(7):658-60. PubMed ID: 17613428
[No Abstract] [Full Text] [Related]
15. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
16. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C
N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665
[No Abstract] [Full Text] [Related]
17. [Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib].
Murase K; Matsunaga T; Takeuchi N; Fujimi A; Takimoto R; Terui T; Hirayama Y; Niitsu Y
Rinsho Ketsueki; 2004 Sep; 45(9):1028-32. PubMed ID: 15510830
[TBL] [Abstract][Full Text] [Related]
18. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
19. Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant.
Martin SE; DellaValla J
Leukemia; 2005 Jun; 19(6):1095-6. PubMed ID: 15789065
[No Abstract] [Full Text] [Related]
20. Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy.
Soderquist C; Bagg A
Blood; 2014 Oct; 124(15):2463. PubMed ID: 25436260
[No Abstract] [Full Text] [Related]
[Next] [New Search]
